News
HUMDF
0.411
NaN%
--
Hua Medicine Advances Diabetes Treatment with New Phase Ib Trial
TipRanks · 12/09 12:09
Hua Medicine Grants Share Options to Drive Growth and Commitment
TipRanks · 12/01 00:37
Hua Medicine Announces Changes to Remuneration Committee
TipRanks · 11/27 10:12
Hua Medicine Updates Board of Directors and Committee Roles
TipRanks · 11/27 10:10
Weekly Report: what happened at HUMDF last week (0908-0912)?
Weekly Report · 09/15 09:46
Weekly Report: what happened at HUMDF last week (0901-0905)?
Weekly Report · 09/08 09:48
Weekly Report: what happened at HUMDF last week (0825-0829)?
Weekly Report · 09/01 09:46
Hua Medicine Reports Strong Growth in 2025
TipRanks · 08/29 03:54
Hua Medicine Reports Strong Growth and Strategic Advancements in 2025 Interim Results
TipRanks · 08/28 08:38
Weekly Report: what happened at HUMDF last week (0818-0822)?
Weekly Report · 08/25 09:49
Weekly Report: what happened at HUMDF last week (0811-0815)?
Weekly Report · 08/18 09:47
Hua Medicine Schedules Board Meeting to Review Interim Results
TipRanks · 08/18 09:22
Weekly Report: what happened at HUMDF last week (0804-0808)?
Weekly Report · 08/11 09:49
Weekly Report: what happened at HUMDF last week (0728-0801)?
Weekly Report · 08/04 09:51
Hua Medicine Reports Significant Profit Turnaround in H1 2025
TipRanks · 07/28 11:07
Weekly Report: what happened at HUMDF last week (0721-0725)?
Weekly Report · 07/28 09:51
Weekly Report: what happened at HUMDF last week (0714-0718)?
Weekly Report · 07/21 09:47
Weekly Report: what happened at HUMDF last week (0707-0711)?
Weekly Report · 07/14 09:50
Weekly Report: what happened at HUMDF last week (0630-0704)?
Weekly Report · 07/07 09:48
Weekly Report: what happened at HUMDF last week (0623-0627)?
Weekly Report · 06/30 09:50
More
Webull provides a variety of real-time HUMDF stock news. You can receive the latest news about Hua Medicine Cay through multiple platforms. This information may help you make smarter investment decisions.
About HUMDF
Hua Medicine is an investment holding company primarily engaged in the development and commercialization of oral drug for the treatment of Type 2 diabetes. The Company is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The Company mainly conducts its businesses in the domestic market.